中文
  • About Us
    Corporate Overview Sr. Management Team Board of Directors
  • Our Science
    Anti-viral Platform RNA Interference Fatty Liver Disease
  • Products & Pipeline
    Overview HCV HBV ASC09 ASC06
  • Partnership
  • Investors
    Financials & Filings
  • News
    2019 2018 2017 2016 2015 2014
  • Careers
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • Ascletis Received IND Approval for its NASH Drug

    2019-08-28

  • Ascletis Opens Clinical Development Shanghai Center

    2019-08-12

  • Ascletis’ Strategic Partner 3-V Biosciences Announced its Name Change and Financing Status

    2019-08-06

  • Ascletis Received IND Approval and Management Outlook of 2019 and Beyond

    2019-08-05

  • Ascletis to Attend Goldman Sachs China Healthcare Corporate Day 2019

    2019-06-24

  • «
  •  
  • 1
  • 2
  • 3
  • 4
  •  
  • »
    • © 2018 Ascletis Pharma Inc.
    • 浙公网安备 33010802003344号
    • All Rights Reserved
    • 浙ICP备 11050387号

    contact

    • pr@ascletis.com
    • bd@ascletis.com
    • hr@ascletis.com
    • clinicaltrials@ascletis.com

    © 2018 Ascletis Pharma Inc. All Rights Reserved
    浙公网安备 33010802003344号 浙ICP备 11050387号